



REGENEX LTD.

FOUNDED

in 2011

[Mini-grant received]

CORE OF THE INNOVATION:

To create autologous cell vaccines for treating autoimmune diseases.

IMPLEMENTATION OF THE DEVELOPMENT

AFTER HOLDING A WIDE-SCALE CLINICAL
TESTING

PEOPLE

GENERAL DIRECTOR:
Vladimir Y. Mukhin

Applications

Preventing exacerbations of diseases for patients with autoimmune diseases, in particular with atherosclerosis, and suppressing “transplant against host” reaction after transplantation of hematopoietic stem cells.

1

Regulatory T cells (Treg) play the key role in the development of autoimmune diseases: the patients show sharply reduced quantity of these cells and genetically conditioned suppression of their functions.

2

The company developed a unique technology of recovering the Treg population by their expansion from the precursor cells out of the body and further infusion of the received Tregs back to the patient.

3

Currently there is no similar commercialized product, and Regenex has all the chances to become the leader in the world market.